We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

APP:NASDAQApplovin Corporation Analysis

Data as of 2026-05-28 - not real-time

$567.83

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

AppLovin delivered a blockbuster Q1 2026 with revenue of $1.84 B, up 59% YoY and beating the consensus $1.77 B estimate. Adjusted EPS surged, sending the stock 3% higher after the release. The company’s margins remain extraordinary—gross margin ~88%, operating margin ~78% and profit margin ~64%—supporting robust cash generation. Technicals are also supportive: the price of $567 sits above the 20‑day and 50‑day SMAs, the MACD is bullish, and RSI at 68.7 signals strong momentum, though it approaches overbought territory. However, valuation metrics are extreme, with a trailing PE of 49 versus an industry average of 17 and a price‑to‑book of over 80, placing the current price well above the DCF‑derived fair value of $337.
Balance‑sheet leverage and volatility temper the optimism: debt‑to‑equity exceeds 160% and ROE is modest at 2.7%, while a beta of 2.24 and 30‑day volatility near 66% indicate high sensitivity to market swings. The “Extreme Greed” sentiment index suggests a potentially crowded trade. Despite these risks, analysts maintain a strong‑buy consensus with an upside potential of about 13‑15% toward the median target of $660, bolstered by an upcoming product milestone in June. Investors must weigh the compelling growth against the pronounced valuation premium and volatility.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Quarterly earnings beat and accelerating revenue growth
  • Bullish technical setup (price above SMAs, MACD bullish)
  • High short‑term momentum despite overbought RSI

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained double‑digit revenue growth and expanding margins
  • Upcoming product milestone expected to deepen platform stickiness
  • Analyst consensus strong‑buy with median target above current price

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Valuation remains far above fundamentals (PE, PB, DCF)
  • Elevated leverage and modest ROE raise capital efficiency concerns
  • High beta and volatility could amplify market downturn impacts

Key Metrics & Analysis

Financial Health

Revenue Growth59.00%
Profit Margin64.29%
P/E Ratio49.2
ROE266.44%
ROA44.24%
Debt/Equity162.89
P/B Ratio80.8
Op. Cash Flow$4.4B
Free Cash Flow$3.2B
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI68.7
Support$430.25
Resistance$581.00
MA 20$482.46
MA 50$451.69
MA 200$534.97
MACDBullish
VolumeStable
Fear & Greed Index91.54

Valuation

Fair Value$337.11
Target Price$644.47
Upside/Downside13.50%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.24
Volatility65.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.